돌아가기
Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
HRID 1455720생성일: 2026년 10월 26일

Methyl 5-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-2-hydroxybenzoate → (-)-Salbutamol

https://huagongshe.com/reaction/1455720

반응식

참여 물질

역할이름HCID투입량
반응물Methyl 5-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-2-hydroxybenzoateHCID 11086725—
반응물(Dimethyl sulfide)trihydroboronHCID 12423031—
반응물Ditoluoyl-l-tartaric acidHCID 129746773—
반응물(+)-di-toluoyl-D-tartaric acidHCID 129858806—
용매MethanolHCID 887—
생성물(-)-SalbutamolHCID 123600—

반응 단계

Several patents report synthetic routes using enantiomeric separation, however, the synthetic routes result in low yields of the enantiomerically pure product. Optically pure levalbuterol was synthesized by the borane-methylsulfide reduction of the enantiomerically pure precursor (Formula 2) as described in U.S. Pat. No. 5,399,765. The reaction dissolved a mixture of enantiomers of methyl 5-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-2-hydroxybenzoate and a chiral acid selected from (−)-di-toluoyl-L-tartaric acid and (+)-di-toluoyl-D-tartaric acid in methanol, upon cooling one stereoisomer crystallized, which was separated, and recrystallized as a diastereomer from methanol, the diastereomer was separated, treated with base, and upon reduction formed optically active levalbuterol.

출처 및 근거

DOI10.6084/m9.figshare.5104873.v1
특허 번호US07482489B2
출처 데이터셋uspto-grants-2009_01
ORD IDord-c07eb2839d6b4c14a590a0ea09564163
출처 메모uspto-grants-2009_01